Venobotic
Automated CVAD Blood Sampling and Flushing for Safer Central-line Care
Company Overview
Snapshot
Founded in March 2025 by Michal Singer, Venobotic operates with 1–10 employees. The company has secured funding across one round from one investor, eHealth Ventures, for its automated medical device platform. In May 2026, Venobotic received Seed funding, marking a significant step in its development.
Business overview
Venobotic develops LineGuard, an automated medical device platform designed for blood sampling, flushing, and disinfection through Central Venous Access Devices (CVADs). This technology aims to standardize workflow, reduce contamination risks, and improve protocol consistency in various healthcare settings, including hospitals, oncology units, ICUs, post-operative wards, community clinics, home infusion, and palliative care. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics markets, serving healthcare providers and laboratories in Israel and the United States.
Strategic signal
In May 2026, Venobotic secured Seed funding from eHealth Ventures. This investment validates the company's innovative approach to central-line care and signals strong investor confidence in its potential to address critical needs in medical device automation and patient safety within the healthcare industry.
Log in to access full profile ›Company Intelligence Q&A
- When was Venobotic founded?
- Venobotic was founded in March 2025.
- Who is a co-founder of Venobotic?
- Michal Singer is a co-founder and Scientific Advisor at Venobotic.
- What is Venobotic's primary product?
- Venobotic's primary product is LineGuard, an automated medical device platform for CVAD blood sampling, flushing, and disinfection.
- What markets does Venobotic serve?
- Venobotic serves healthcare providers and laboratories in geomarkets including Israel and the United States.